malignant pleural mesothelioma (Cancer)
Information
- Disease name
- malignant pleural mesothelioma
- Disease ID
- DOID:7474
- Description
- "A pleural cancer that has_material_basis_in mesothelium cells." [url:http\://en.wikipedia.org/wiki/Mesothelioma]
Disease area statistics
Chromosome band
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03710876 | Active, not recruiting | Phase 3 | Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma | January 21, 2019 | November 2024 |
| NCT02863055 | Active, not recruiting | Phase 2 | Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma | February 4, 2018 | March 31, 2024 |
| NCT02611037 | Active, not recruiting | Phase 2 | Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma | March 4, 2016 | December 2024 |
| NCT02436733 | Active, not recruiting | Phase 2 | Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM | September 20, 2016 | September 2023 |
| NCT02649829 | Active, not recruiting | Phase 1/Phase 2 | Autologous Dendritic Cell Vaccination in Mesothelioma | August 1, 2017 | March 2025 |
| NCT04334759 | Active, not recruiting | Phase 3 | DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma | February 18, 2021 | December 2025 |
| NCT04480372 | Active, not recruiting | Phase 2 | SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II | March 17, 2021 | May 2024 |
| NCT00797719 | Active, not recruiting | Phase 1/Phase 2 | Short Neoadjuvant Hemithoracic IMRT for MPM | October 2008 | September 2024 |
| NCT04162015 | Active, not recruiting | Phase 1 | A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma | November 12, 2019 | November 2025 |
| NCT05308966 | Active, not recruiting | Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE) | May 3, 2022 | April 1, 2025 | |
| NCT00738582 | Completed | Phase 2 | An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma | December 31, 2008 | January 10, 2014 |
| NCT00867711 | Completed | Molecular Predictors of Pemetrexed and Carboplatin Response in Malignant Pleural Mesothelioma (MPM) Patients | January 2009 | December 2011 | |
| NCT01024946 | Completed | Phase 2 | Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity | December 2009 | July 2012 |
| NCT01098266 | Completed | Phase 3 | NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed | April 12, 2010 | December 2017 |
| NCT01211275 | Completed | Phase 1/Phase 2 | Standard Chemotherapy With of Without Axitinib in Malignant Mesothelioma | May 22, 2009 | May 6, 2013 |
| NCT01212367 | Completed | Phase 1 | Intrapleural Gene Transfer for Pleural Mesothelioma | February 2009 | May 2015 |
| NCT01265433 | Completed | Phase 2 | WT-1 Analog Peptide Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy | December 21, 2010 | July 25, 2017 |
| NCT01355965 | Completed | Phase 1 | Autologous Redirected RNA Meso-CIR T Cells | May 2011 | October 2015 |
| NCT01486368 | Completed | Phase 2 | A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma | June 26, 2012 | February 13, 2015 |
| NCT01644994 | Completed | Phase 1/Phase 2 | Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma | November 2012 | August 2021 |
| NCT01675765 | Completed | Phase 1 | Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma | September 3, 2014 | August 19, 2019 |
| NCT01721018 | Completed | Phase 1/Phase 2 | Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma. | October 2012 | November 14, 2016 |
| NCT01722149 | Completed | Early Phase 1 | Re-directed T Cells for the Treatment (FAP)-Positive Malignant Pleural Mesothelioma | February 19, 2015 | July 18, 2019 |
| NCT01865045 | Completed | Pharmacogenetics Of Vinorelbine In Malignant Pleural Mesothelioma Patients | November 2012 | December 2017 | |
| NCT02049060 | Completed | Phase 1/Phase 2 | Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin | January 2013 | December 2017 |
| NCT02194231 | Completed | Phase 2 | ATREUS - Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM) | July 2013 | December 12, 2019 |
| NCT02269878 | Completed | Effect of FAS and FAS Ligand Polymorphisms on Patients With Platinum-Based -Treated Malignant Pleural Mesothelioma | April 2014 | December 2016 | |
| NCT02347917 | Completed | Phase 1/Phase 2 | A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma | February 2015 | May 31, 2018 |
| NCT02369198 | Completed | Phase 1 | MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC | September 2014 | January 4, 2017 |
| NCT02397928 | Completed | Phase 2 | Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR) | February 2015 | April 2018 |
| NCT01243632 | Completed | Phase 2 | Gemcitabine in Long Infusion and Cisplatin for Malignant Pleural Mesothelioma Treatment | December 2002 | June 2010 |
| NCT00165516 | Completed | Phase 2 | Extrapleural Pneumonectomy With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Amifostine and Sodium Thiosulfate | January 2004 | December 2009 |
| NCT00165555 | Completed | Phase 1 | Pleurectomy/Decortication Followed by Intrathoracic/Intraperitoneal Heated Cisplatin for Malignant Pleural Mesothelioma | August 1999 | November 2009 |
| NCT00272558 | Completed | Phase 2 | Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma | September 2004 | September 2009 |
| NCT00280982 | Completed | Phase 1 | Dendritic Cell-based Immunotherapy in Mesothelioma | January 2006 | September 2009 |
| NCT00386815 | Completed | Phase 2 | Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma | October 2006 | February 2007 |
| NCT00484276 | Completed | Phase 2 | Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma | May 2007 | March 2013 |
| NCT00571298 | Completed | Phase 1 | Extrapleural Pneumonectomy /Pleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma | November 2007 | June 2015 |
| NCT00652574 | Completed | Phase 1 | Dasatinib in Resectable Malignant Pleural Mesothelioma | March 12, 2008 | October 7, 2022 |
| NCT00700336 | Completed | Phase 1/Phase 2 | Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II) | May 2008 | November 2012 |
| NCT02497508 | Completed | Phase 2 | Nivolumab in Patients With Recurrent Malignant Mesothelioma | July 2015 | July 2017 |
| NCT02662504 | Completed | Phase 2 | Intrapleural Photodynamic Therapy in a Multimodal Treatment for Patients With Malignant Pleural Mesothelioma | January 16, 2016 | March 13, 2018 |
| NCT03048474 | Completed | Phase 2 | Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma | September 2016 | December 2019 |
| NCT03177668 | Completed | Phase 1/Phase 2 | Clinical Study of YS110 in Patients With Malignant Pleural Mesothelioma | August 8, 2017 | February 5, 2020 |
| NCT03412357 | Completed | N/A | MesoTRAP: A Study Comparing Video-assisted Thoracoscopic Partial Pleurectomy/Decortication With Indwelling Pleural Catheter in Patients With Trapped Lung Due to Malignant Pleural Mesothelioma. | August 10, 2017 | August 1, 2020 |
| NCT04775446 | Completed | Evaluation of the Clinical/Biological Characteristics, Efficacy and Safety of Patients With Malignant Pleural Mesothelioma, Treated by Immunotherapy | November 26, 2020 | October 11, 2021 | |
| NCT04843007 | Completed | Alvopem® (Pemetrexed) Safety Assessment | October 5, 2016 | January 22, 2020 | |
| NCT06318286 | Not yet recruiting | Phase 2 | Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma | March 13, 2024 | October 30, 2026 |
| NCT05425576 | Not yet recruiting | Phase 2 | OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition | June 2025 | December 2029 |
| NCT04713761 | Not yet recruiting | Phase 2 | Neoadjuvant Toripalimab Combined With Chemotherapy in the Treatment of Malignant Pleural Mesothelioma | February 1, 2021 | May 31, 2025 |
| NCT03269227 | Recruiting | N/A | Accelerated Hypofractionated Radiotherapy in the Treatment of Malignant Pleural Mesothelioma | August 14, 2017 | December 2023 |
| NCT05795595 | Recruiting | Phase 1/Phase 2 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors | March 13, 2023 | May 2030 |
| NCT05655078 | Recruiting | N/A | Hemithoracic Irradiation With Proton Therapy in Malignant Pleural Mesothelioma | March 28, 2024 | September 30, 2029 |
| NCT05660616 | Recruiting | Phase 2 | Switch-Maintenance Gemcitabine After First-Line Chemotherapy In Patients With Malignant Pleural Mesothelioma | April 1, 2023 | December 2024 |
| NCT05765084 | Recruiting | Phase 1/Phase 2 | Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma | February 24, 2023 | October 2026 |
| NCT03715933 | Recruiting | Phase 1 | Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | October 10, 2018 | July 2026 |
| NCT03917043 | Recruiting | Phase 1 | APG-2449 in Patients With Advanced Solid Tumors | May 27, 2019 | February 2025 |
| NCT04400539 | Recruiting | Phase 2 | The IMmunotherapy Pleural 5-ALA PDT | May 9, 2022 | May 2026 |
| NCT04525859 | Recruiting | Phase 1 | Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma | August 19, 2020 | August 31, 2024 |
| NCT06037941 | Recruiting | N/A | Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma | September 8, 2023 | September 2025 |
| NCT04897022 | Recruiting | Phase 1 | A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma | August 10, 2021 | August 2026 |
| NCT05278975 | Recruiting | Phase 1/Phase 2 | Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma | March 31, 2022 | April 1, 2025 |
| NCT05498597 | Recruiting | Phase 1 | AMT-151 in Patients With Selected Advanced Solid Tumours | January 25, 2023 | October 30, 2024 |
| NCT05508555 | Recruiting | N/A | Effect of HITHOC After Pleurectomy Decortication for Treatment of Malignant Pleural Mesothelioma | March 1, 2022 | November 2024 |
| NCT01870609 | Terminated | Phase 2 | Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma | September 2013 | January 2016 |
| NCT02004028 | Terminated | Phase 2 | Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants | December 12, 2013 | June 19, 2019 |
| NCT00165503 | Terminated | Phase 2 | Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate | April 2004 | July 2010 |
| NCT01143545 | Terminated | Phase 1 | Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas | December 7, 2010 | February 26, 2020 |
| NCT03175172 | Terminated | Phase 2 | Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM) | May 31, 2017 | January 31, 2018 |
| NCT01279967 | Unknown status | Phase 2 | A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural Mesothelioma | January 2011 | March 2015 |
| NCT02755675 | Unknown status | Phase 2 | uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung | April 2016 | October 2023 |
| NCT04013334 | Unknown status | Phase 2 | MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma | August 15, 2019 | January 1, 2023 |
| NCT00969098 | Unknown status | Response Evaluation in Malignant Pleural Mesothelioma | June 2009 | September 2015 | |
| NCT01343264 | Unknown status | Trimodality Therapy for Malignant Pleural Mesothelioma | November 2002 | ||
| NCT05042557 | Unknown status | Real World Study of MPM in China | June 1, 2021 | December 20, 2022 | |
| NCT00886028 | Unknown status | Phase 2 | Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma | September 2006 | June 2009 |
| NCT02761863 | Unknown status | Effect of Expression of CD74 and VEGF on Outcome of Treatment in Patients With Malignant Pleural Mesothelioma | July 30, 2019 | July 30, 2021 | |
| NCT02497053 | Unknown status | Phase 2 | Four Versus Six Cycles of Pemetrexed/Platinum for MPM | June 2015 | |
| NCT04201145 | Withdrawn | Phase 1 | Pembrolizumab + Defactinib In Pleural Mesothelioma | September 2020 | December 31, 2022 |
| NCT02639767 | Withdrawn | Phase 1 | Concurrent Pemetrexed/Cisplatin With Pleural Intensity Modulated Radiation Therapy for Patients With Unresectable Malignant Pleural Mesothelioma | December 2015 | |
| NCT05582031 | Withdrawn | Phase 2 | Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers | April 30, 2023 | April 30, 2025 |
| NCT01353482 | Withdrawn | Phase 1/Phase 2 | A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma |
- Disase is a (Disease Ontology)
- DOID:5158
- Cross Reference ID (Disease Ontology)
- ICD10CM:C45.0
- Cross Reference ID (Disease Ontology)
- MESH:D000086002
- Cross Reference ID (Disease Ontology)
- NCI:C7376
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:254645002
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0812413
- Exact Synonym (Disease Ontology)
- malignant mesothelioma of pleura